Phase II study of liposomal amphotericin B for febrile neutropenia.(C-SHOT1001)

Phase II study of liposomal amphotericin B for febrile neutropenia.(C-SHOT1001) - L-AMB for FN.(C-SHOT1001)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003185

Enrollment

Registered

2010-02-15

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

Empirical therapy of L-AMB

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with haematological malignancies accompanied by febrile neutropenia who do not respond to antibiotics. Age ranging from 16 to 79.

Exclusion criteria

Exclusion criteria: (1) Allergy to L-AMB (2) Infection with proven pathogens (3) HIV-antibody positive (4) Pregnant or lactating patients (5) Patients after allogeneic stem cell transplantation (6) Invasive fungal infections (7) Those considered inappropriate to be participated

Design outcomes

Primary

Measure	Time frame
Keeping up body temperature under 38degrees celcius for 48 hours. No invasive fungal infection No change of antifungal agents No interruption of treatment due to adverse reactions *Patient survival	—

Secondary

Measure	Time frame
Frequencies of adverse reactions Alleviation of fever *The therapy finished.	—

Countries

Japan

Contacts

Public ContactMasashi Sawa

Anjo Kosei Hospital Department hematology and oncology

support@c-shot.or.jp0566-75-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026